CORPORATE PROFILE

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.

Click here for information on our marketed product Rubraca® (rucaparib).

Our first product, Rubraca® (rucaparib) tablets, is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1, 2 and 3. In December 2016, Rubraca became the first PARP approved by the U.S. Food and Drug Administration (FDA) as monotherapy for treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more prior chemotherapies. We submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for this indication in late 2016, and expect a CHMP opinion in 2017. For information on our marketed product, click here.

In June 2017, we announced topline results from the phase 3 ARIEL3 trial, which evaluated rucaparib as maintenance treatment in patients with advanced ovarian cancer. Based on these results, the Company intends to pursue an expanded label to potentially help a broader population of women with platinum-sensitive, advanced ovarian cancer beyond the current Rubraca treatment indication.

Our TRITON clinical development program, with two trials currently enrolling (TRITON2 and TRITON3), is evaluating rucaparib in metastatic castration-resistant prostate cancer (mCRPC).

Rucaparib is also under development for additional ovarian cancer indications and studies are open for enrollment or under consideration in several other solid tumor types, including prostate, breast, pancreatic, gastroesophageal, bladder and lung cancers. These include both monotherapy and combination studies.

By pursuing a thorough scientific understanding of rucaparib and sharing these insights with the clinical community, we hope to make contributions that move the entire field forward and help change the cancer treatment paradigm. We maintain worldwide rights to rucaparib.

Clovis Oncology's management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company's vision. Clovis is headquartered in Boulder, Colorado, with offices in San Francisco, California, and Cambridge, United Kingdom.